<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/cdmo-services_2505197529-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/cdmo-services_2505197529-430x241.jpg"/></p>
<p>CDMO 的垂直整合有其优缺点。来源：Shutterstock。</p>
<p>参与抗体药物偶联物（ADCs）生产的合同开发和制造组织（CDMOs）的垂直整合有潜力简化供应链并降低成本。然而，这也带来了挑战，特别是在保持每个生产阶段的专业知识方面。</p>
<p>ADCs 是复杂的治疗药物，将单克隆抗体（MAbs）与细胞毒性药物结合，使其能够针对癌细胞进行治疗，同时最小化对健康组织的损害。由于其复杂性，ADCs 的生产通常需要多个 CDMOs，每个 CDMO 在不同阶段具有专业知识。</p>
<p>CDMOs 在确保一致的高产量生产以满足日益增长的 ADCs 市场需求方面也发挥着至关重要的作用，同时还需应对复杂的监管和合规要求。</p>
<p>根据 GlobalData 的预测，到 2025 年，ADCs 预计将成为增长最快的治疗类别，目前有 268 种 ADCs 药物正在临床开发中。然而，迄今为止，只有 6% 的 ADCs 已商业化，这表明未来几年市场潜力巨大。</p>
<p>随着对 ADCs 需求的上升，将生产整合在单一的垂直整合 CDMO 内可以带来可观的成本节约和更大的韧性。通过简化操作和改善生产阶段之间的沟通，垂直整合可以减少对国际合作伙伴的依赖，从而降低中断风险。然而，这种模式并非没有缺点。</p>
<h2>ADC 生产中垂直整合的优势</h2>
<p>ADCs 是一类复杂的靶向癌症治疗药物，具有高度专业化的要求。</p>
<p>垂直整合使公司能够监督 ADCs 生产的每一个步骤，从 MAbs 的合成到药物 - 连接子偶联物的制造。这确保了对最终产品质量和一致性的更大控制，这对 ADCs 的安全性和有效性至关重要。由于 ADCs 的生产对组件的微小变化高度敏感，保持控制可以防止导致生产延迟或质量问题的不一致。</p>
<p>在 ADCs 生产中，关键组件如细胞毒性药物、连接子和抗体必须从可靠的供应商处采购。垂直整合模型通过减少对外部供应商的依赖，简化了供应链，同时缩短了交货时间并降低了中断风险。这在临床试验或商业规模生产期间尤为重要，因为延迟可能会带来重大的财务和监管后果。</p>
<p>此外，垂直整合减少了对第三方合同和外包的需求。结果是在制造、物流和质量控制等领域可能节省成本。这在为商业化扩大 ADCs 生产规模时尤其有利，因为内部生产可以降低每单位成本并改善整体利润率。</p>
<p>通过对整个生产过程的直接监督，垂直整合的公司可以更迅速地应对变化，调整生产计划，并确保更快的上市时间。在快速变化的生物制药市场中，速度可能是获得市场份额或失去市场份额的关键，这一点尤其重要。</p>
<p>此外，对垂直整合的更大控制可以简化监管提交和批准。</p>
<p>内部控制生产过程可以更好地保护专有信息和知识产权。ADCs 通常是复杂专有技术的结果，垂直整合的公司在保护其知识产权方面处于更有利的位置，因为它们可以将关键流程和技术保留在内部。这降低了知识泄露的风险，并增强了对有价值资产的保护。</p>
<h2>ADC 生产中垂直整合的缺点</h2>
<p>垂直整合的最大缺点之一是建立和维护必要基础设施所需的巨额前期资本。在 ADCs 生产中，这可能涉及建立先进的制造设施、采购专业设备和雇用高技能人员。对一些公司，尤其是较小或早期阶段的生物制药公司来说，投资生产设施、研发和监管合规的成本可能过于高昂。</p>
<p>管理整个生产过程，从原材料采购到最终产品分发，可能是复杂的，并且需要在各个学科中具备高水平的专业知识。对于 ADCs 生产，这包括处理敏感的生物材料、确保每个步骤的质量控制以及应对监管障碍。对于许多公司来说，管理如此广泛的操作范围的复杂性可能导致低效率和有效扩大生产的困难。</p>
<p>垂直整合可能导致资源的过度扩展，无论是在财务还是人力资本方面。试图承担过多的公司可能会发现难以维持高质量 ADCs 生产所需的专业化水平。此外，过于专注于内部生产可能会削弱公司的核心竞争力，或导致在其他业务领域（如研发或商业化）错失机会。</p>
<p>虽然垂直整合提供了更多的控制权，但也可能降低公司在市场或监管环境变化时的灵活性。例如，一家在特定生产设施或技术上进行了大量投资的公司，可能在转变或采用新的、更高效的方法时反应缓慢。此外，如果出现内部生产问题，可能会导致整个生产链的停滞，从而延迟关键时间表并影响市场准备情况。</p>
<p>在 ADC 生产中的垂直整合也可能引入显著的监管挑战。由于其复杂性及其成分（特别是使用的细胞毒性药物）所带来的风险，ADC 受到严格监管。在垂直整合的供应链中管理监管合规性需要大量的资源和专业知识。在生产的每个环节未能维持必要的监管标准可能导致延误、罚款，甚至在关键市场被拒绝产品。</p>
<p>巨额的资本投资、运营复杂性和过度扩展的潜在风险可能会给特别是小型公司带来障碍。</p>
<p>最终，是否进行垂直整合的决策应根据具体情况进行权衡，考虑潜在的好处与固有的风险。公司必须仔细评估其资源、能力和长期战略，然后再决定是否承诺于完全整合的生产模式。</p>
<h2>完全垂直整合的有效替代方案</h2>
<p>虽然垂直整合可以是一个有吸引力的模式，但在快速发展的 ADC 领域，它并不总是最实用或高效的方法。一些参与者采用的替代策略是将对关键制造步骤的深厚专业知识与在 ADC 价值链中精心选择的合作伙伴相结合。</p>
<p>Indena 通过其对载体和连接子开发的强烈关注，结合在 GMP 高效能化学方面的长期经验，展示了这一方法。在这一阶段，公司并未提供完全的垂直整合，而是与专门的 CDMO 在生物偶联和抗体方面合作，使客户能够访问有效整合的 ADC 制造路径，同时在每个阶段保持灵活性和技术深度。</p>
<p>与此同时，这种以合作伙伴为主导的模式并不排除未来的整合。Indena 正在积极评估在 ADC CDMO 能力（包括生物偶联）方面的重大投资，以评估如何最好地将其内部优势与 ADC 开发者不断变化的需求对齐。这种适应性策略反映了更广泛的行业趋势：优先考虑科学专业知识和客户需求，同时保留在市场成熟时向更大整合扩展的选项。</p>
<h2>高质量的 ADC 生产服务</h2>
<p>在 ADC 生产中的垂直整合提供了成本节约、简化供应链和提高韧性的潜力。然而，它也面临着确保在所有生产阶段保持一致专业知识的挑战，这需要在培训、技术和质量控制流程上进行大量投资。</p>
<p>对于寻求有效替代完全垂直整合的公司，Indena 提供了一个值得信赖的全面解决方案。通过与行业领导者合作并投资于创新技术，Indena 确保其客户能够获得符合监管标准并提供安全、有效疗法的高质量、可靠的 ADC 生产服务。</p>
<p><strong><em>要了解更多关于 Indena 的服务和解决方案，请下载下面的文档。</em></strong></p>

ADCT

<p>抗体药物偶联物（ADCs）制造中的合同开发和制造组织（CDMOs）的垂直整合可以降低成本并增强供应链的韧性。虽然这可以更好地控制生产质量和一致性，但也带来了高额的前期资本成本和管理多样化运营的复杂性等挑战。预计 ADCs 市场将显著增长，目前有 268 种药物处于临床开发中，这突显了尽管存在缺点，垂直整合模式的潜在好处</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/cdmo-services_2505197529-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/cdmo-services_2505197529-430x241.jpg"/></p>
<p>There are advantages and disadvantages for vertical integration of CDMOs. Credit: via Shutterstock.</p>
<div class="lb-trans"><p>CDMO 的垂直整合有其优缺点。来源：Shutterstock。</p>
</div><p>Vertical integration of contract development and manufacturing organisations (CDMOs) involved in antibody-drug conjugates (ADCs) manufacturing has the potential to streamline supply chains and drive cost reductions. However, it also introduces challenges, particularly when it comes to maintaining expertise across every stage of production.</p>
<div class="lb-trans"><p>参与抗体药物偶联物（ADCs）生产的合同开发和制造组织（CDMOs）的垂直整合有潜力简化供应链并降低成本。然而，这也带来了挑战，特别是在保持每个生产阶段的专业知识方面。</p>
</div><p>ADCs are sophisticated therapeutic agents that combine monoclonal antibodies (MAbs) with cytotoxic drugs, enabling targeted treatment of cancer cells while minimising damage to healthy tissue. Due to their complexity, the manufacturing of ADCs typically requires multiple CDMOs, each with specialised expertise at different phases of the process.</p>
<div class="lb-trans"><p>ADCs 是复杂的治疗药物，将单克隆抗体（MAbs）与细胞毒性药物结合，使其能够针对癌细胞进行治疗，同时最小化对健康组织的损害。由于其复杂性，ADCs 的生产通常需要多个 CDMOs，每个 CDMO 在不同阶段具有专业知识。</p>
</div><p>CDMOs also play a vital role in ensuring consistent, high-volume production to meet the growing market demand for ADCs, while navigating complex regulatory and compliance requirements.</p>
<div class="lb-trans"><p>CDMOs 在确保一致的高产量生产以满足日益增长的 ADCs 市场需求方面也发挥着至关重要的作用，同时还需应对复杂的监管和合规要求。</p>
</div><p>According to GlobalData, ADCs are expected to emerge as the fastest-growing class of therapies by 2025, with 268 ADC drugs currently in clinical development. However, only 6% of ADCs have been commercially launched to date, suggesting significant market potential in the coming years.</p>
<div class="lb-trans"><p>根据 GlobalData 的预测，到 2025 年，ADCs 预计将成为增长最快的治疗类别，目前有 268 种 ADCs 药物正在临床开发中。然而，迄今为止，只有 6% 的 ADCs 已商业化，这表明未来几年市场潜力巨大。</p>
</div><p>With demand for ADCs on the rise, consolidating production within a single vertically integrated CDMO can deliver substantial cost savings and greater resilience. By streamlining operations and improving communication across production stages, vertical integration can reduce dependency on international partners, minimising risks of disruption. However, the model is not without its drawbacks.</p>
<div class="lb-trans"><p>随着对 ADCs 需求的上升，将生产整合在单一的垂直整合 CDMO 内可以带来可观的成本节约和更大的韧性。通过简化操作和改善生产阶段之间的沟通，垂直整合可以减少对国际合作伙伴的依赖，从而降低中断风险。然而，这种模式并非没有缺点。</p>
</div><h2>Advantages of vertical integration in ADC production</h2>
<div class="lb-trans"><h2>ADC 生产中垂直整合的优势</h2>
</div><p>ADCs are a complex class of targeted cancer therapies with highly specialised requirements.</p>
<div class="lb-trans"><p>ADCs 是一类复杂的靶向癌症治疗药物，具有高度专业化的要求。</p>
</div><p>Vertical integration allows companies to oversee every step of ADC production, from the synthesis of MAbs to the manufacturing of the drug-linker conjugate. This ensures greater control over the quality and consistency of the final product, which is critical for the safety and efficacy of ADCs. Because ADC production is highly sensitive to even small variations in components, maintaining control can prevent inconsistencies that may lead to production delays or quality concerns.</p>
<div class="lb-trans"><p>垂直整合使公司能够监督 ADCs 生产的每一个步骤，从 MAbs 的合成到药物 - 连接子偶联物的制造。这确保了对最终产品质量和一致性的更大控制，这对 ADCs 的安全性和有效性至关重要。由于 ADCs 的生产对组件的微小变化高度敏感，保持控制可以防止导致生产延迟或质量问题的不一致。</p>
</div><p>In ADC production, critical components such as cytotoxic drugs, linkers, and antibodies must be sourced from reliable vendors. A vertically integrated model simplifies the supply chain by reducing reliance on external suppliers for key components, along with decreasing lead times and mitigating risks with disruptions. This can be particularly important during clinical trials or commercial-scale production, where delays could have significant financial and regulatory consequences.</p>
<div class="lb-trans"><p>在 ADCs 生产中，关键组件如细胞毒性药物、连接子和抗体必须从可靠的供应商处采购。垂直整合模型通过减少对外部供应商的依赖，简化了供应链，同时缩短了交货时间并降低了中断风险。这在临床试验或商业规模生产期间尤为重要，因为延迟可能会带来重大的财务和监管后果。</p>
</div><p>In addition, vertical integration reduces the need for third-party contracts and outsourcing. The result is potential cost savings in areas such as manufacturing, logistics, and quality control. This can be especially beneficial when scaling up ADC production for commercialisation, as in-house production can reduce the cost per unit and improve overall margins.</p>
<div class="lb-trans"><p>此外，垂直整合减少了对第三方合同和外包的需求。结果是在制造、物流和质量控制等领域可能节省成本。这在为商业化扩大 ADCs 生产规模时尤其有利，因为内部生产可以降低每单位成本并改善整体利润率。</p>
</div><p>With direct oversight of the entire production process, vertically integrated companies can react more swiftly to changes, adjust production schedules, and ensure a faster time-to-market. In the fast-moving biopharmaceutical market, where speed can be the difference between securing market share or losing it to competitors, this is particularly crucial.</p>
<div class="lb-trans"><p>通过对整个生产过程的直接监督，垂直整合的公司可以更迅速地应对变化，调整生产计划，并确保更快的上市时间。在快速变化的生物制药市场中，速度可能是获得市场份额或失去市场份额的关键，这一点尤其重要。</p>
</div><p>Additionally, the greater control over vertically integrated allows for streamlined regulatory submissions and approvals.</p>
<div class="lb-trans"><p>此外，对垂直整合的更大控制可以简化监管提交和批准。</p>
</div><p>Controlling the production process internally can better safeguard proprietary information and intellectual property. ADCs are often the result of complex proprietary technologies, and vertically integrated companies are in a better position to protect their IP by keeping key processes and technologies in-house. This reduces the risk of knowledge leaks and enhances the protection of valuable assets.</p>
<div class="lb-trans"><p>内部控制生产过程可以更好地保护专有信息和知识产权。ADCs 通常是复杂专有技术的结果，垂直整合的公司在保护其知识产权方面处于更有利的位置，因为它们可以将关键流程和技术保留在内部。这降低了知识泄露的风险，并增强了对有价值资产的保护。</p>
</div><h2>Disadvantages of vertical integration in ADC production</h2>
<div class="lb-trans"><h2>ADC 生产中垂直整合的缺点</h2>
</div><p>One of the biggest drawbacks with vertical integration is the significant upfront capital required to build and maintain the necessary infrastructure. In ADC production, this could involve setting up advanced manufacturing facilities, acquiring specialised equipment, and hiring highly skilled personnel. The cost of investing in production facilities, research and development, and regulatory compliance can be prohibitively high for some companies, especially smaller or early-stage biopharma firms.</p>
<div class="lb-trans"><p>垂直整合的最大缺点之一是建立和维护必要基础设施所需的巨额前期资本。在 ADCs 生产中，这可能涉及建立先进的制造设施、采购专业设备和雇用高技能人员。对一些公司，尤其是较小或早期阶段的生物制药公司来说，投资生产设施、研发和监管合规的成本可能过于高昂。</p>
</div><p>Managing the entire production process, from raw material sourcing to final product distribution, can be complex and require a high level of expertise across various disciplines. For ADC production, this includes the handling of sensitive biological materials, ensuring quality control at every step, and dealing with regulatory hurdles. For many companies, the complexity of managing such a broad scope of operations can lead to inefficiencies and difficulties in scaling production effectively.</p>
<div class="lb-trans"><p>管理整个生产过程，从原材料采购到最终产品分发，可能是复杂的，并且需要在各个学科中具备高水平的专业知识。对于 ADCs 生产，这包括处理敏感的生物材料、确保每个步骤的质量控制以及应对监管障碍。对于许多公司来说，管理如此广泛的操作范围的复杂性可能导致低效率和有效扩大生产的困难。</p>
</div><p>Vertical integration can lead to overextension of resources, both in terms of finances and human capital. A company that tries to take on too much may find it difficult to maintain the level of specialisation needed for high-quality ADC production. There is also the risk that focusing too heavily on internal production may detract from the company’s core competencies or lead to missed opportunities in other areas of the business such as research or commercialisation.</p>
<div class="lb-trans"><p>垂直整合可能导致资源的过度扩展，无论是在财务还是人力资本方面。试图承担过多的公司可能会发现难以维持高质量 ADCs 生产所需的专业化水平。此外，过于专注于内部生产可能会削弱公司的核心竞争力，或导致在其他业务领域（如研发或商业化）错失机会。</p>
</div><p>While vertical integration offers more control, it can also reduce a company’s flexibility in adapting to changes in the market or regulatory environment. For instance, a company that has heavily invested in a specific production facility or technology may be slow to pivot or adopt new, more efficient methods. Furthermore, if an internal production issue arises, it could halt the entire production chain, potentially delaying critical timelines and impacting market readiness.</p>
<div class="lb-trans"><p>虽然垂直整合提供了更多的控制权，但也可能降低公司在市场或监管环境变化时的灵活性。例如，一家在特定生产设施或技术上进行了大量投资的公司，可能在转变或采用新的、更高效的方法时反应缓慢。此外，如果出现内部生产问题，可能会导致整个生产链的停滞，从而延迟关键时间表并影响市场准备情况。</p>
</div><p>Vertical integration in ADC production can also introduce significant regulatory challenges. ADCs are highly regulated due to their complexity and the risk associated with their components, particularly the cytotoxic drugs used. Managing regulatory compliance across a vertically integrated supply chain requires significant resources and expertise. Failing to maintain the necessary regulatory standards at every step of production can lead to delays, fines, or even the rejection of products in critical markets.</p>
<div class="lb-trans"><p>在 ADC 生产中的垂直整合也可能引入显著的监管挑战。由于其复杂性及其成分（特别是使用的细胞毒性药物）所带来的风险，ADC 受到严格监管。在垂直整合的供应链中管理监管合规性需要大量的资源和专业知识。在生产的每个环节未能维持必要的监管标准可能导致延误、罚款，甚至在关键市场被拒绝产品。</p>
</div><p>The substantial capital investment, operational complexity, and potential for overextension can create hurdles, particularly for smaller firms.</p>
<div class="lb-trans"><p>巨额的资本投资、运营复杂性和过度扩展的潜在风险可能会给特别是小型公司带来障碍。</p>
</div><p>Ultimately, the decision to vertically integrate should be made on a case-by-case basis, weighing the potential benefits against the inherent risks. Companies must carefully assess their resources, capabilities, and long-term strategy before committing to a fully integrated production model.</p>
<div class="lb-trans"><p>最终，是否进行垂直整合的决策应根据具体情况进行权衡，考虑潜在的好处与固有的风险。公司必须仔细评估其资源、能力和长期战略，然后再决定是否承诺于完全整合的生产模式。</p>
</div><h2>An effective alternative to full vertical integration</h2>
<div class="lb-trans"><h2>完全垂直整合的有效替代方案</h2>
</div><p>While vertical integration can be an attractive model, it is not always the most practical or efficient approach in the rapidly evolving ADC landscape. An alternative strategy adopted by some players is to combine deep expertise in critical manufacturing steps with carefully selected partnerships across the ADC value chain.</p>
<div class="lb-trans"><p>虽然垂直整合可以是一个有吸引力的模式，但在快速发展的 ADC 领域，它并不总是最实用或高效的方法。一些参与者采用的替代策略是将对关键制造步骤的深厚专业知识与在 ADC 价值链中精心选择的合作伙伴相结合。</p>
</div><p>Indena illustrates this approach through its strong focus on payload and linker development, supported by long-standing experience in GMP high-potency chemistry. Rather than providing full vertical integration at this stage, the company collaborates with specialised CDMOs in bioconjugation and antibodies, allowing clients to access an effectively integrated ADC manufacturing pathway while maintaining flexibility and technical depth at each stage.</p>
<div class="lb-trans"><p>Indena 通过其对载体和连接子开发的强烈关注，结合在 GMP 高效能化学方面的长期经验，展示了这一方法。在这一阶段，公司并未提供完全的垂直整合，而是与专门的 CDMO 在生物偶联和抗体方面合作，使客户能够访问有效整合的 ADC 制造路径，同时在每个阶段保持灵活性和技术深度。</p>
</div><p>At the same time, this partnership-led model does not preclude future integration. Indena is actively evaluating significant investments in ADC CDMO capabilities, including bioconjugation, as it assesses how best to align its internal strengths with the evolving needs of ADC developers. This adaptive strategy reflects a broader industry trend: prioritising scientific expertise and client requirements first, while retaining the option to expand towards greater integration as the market matures.</p>
<div class="lb-trans"><p>与此同时，这种以合作伙伴为主导的模式并不排除未来的整合。Indena 正在积极评估在 ADC CDMO 能力（包括生物偶联）方面的重大投资，以评估如何最好地将其内部优势与 ADC 开发者不断变化的需求对齐。这种适应性策略反映了更广泛的行业趋势：优先考虑科学专业知识和客户需求，同时保留在市场成熟时向更大整合扩展的选项。</p>
</div><h2>High-quality ADC production services</h2>
<div class="lb-trans"><h2>高质量的 ADC 生产服务</h2>
</div><p>Vertical integration in ADC production offers the potential for cost savings, streamlined supply chains, and improved resilience. However, it comes with the challenge of ensuring consistent expertise across all phases of production, which requires significant investment in training, technology, and quality control processes.</p>
<div class="lb-trans"><p>在 ADC 生产中的垂直整合提供了成本节约、简化供应链和提高韧性的潜力。然而，它也面临着确保在所有生产阶段保持一致专业知识的挑战，这需要在培训、技术和质量控制流程上进行大量投资。</p>
</div><p>For companies seeking an effective alternative to full vertical integration, Indena provides a trusted, comprehensive solution. By partnering with industry leaders and investing in innovative technologies, Indena ensures that its clients have access to high-quality, reliable ADC production services that meet regulatory standards and deliver safe, effective therapies.</p>
<div class="lb-trans"><p>对于寻求有效替代完全垂直整合的公司，Indena 提供了一个值得信赖的全面解决方案。通过与行业领导者合作并投资于创新技术，Indena 确保其客户能够获得符合监管标准并提供安全、有效疗法的高质量、可靠的 ADC 生产服务。</p>
</div><p><strong><em>To learn more about Indena’s services and solutions, download the document below.</em></strong></p>
<div class="lb-trans"><p><strong><em>要了解更多关于 Indena 的服务和解决方案，请下载下面的文档。</em></strong></p>
</div>

垂直整合的合同开发与生产组织（CDMO）：对抗体药物偶联物（ADCs）的优缺点